Key Stats for Intuitive Surgical Stock
- 52-Week Range: $427.8 to $603.9
- Current Price: $459
- Street Mean Target: $599.2
- Street High Target: $378
- TIKR Model Target (Dec. 2030): $849.2
What Happened?
Intuitive Surgical (ISRG), the maker of da Vinci robotic surgery systems used in minimally invasive procedures ranging from cancer removal to hernia repair, delivered a 2025 that rewrote its own growth record on multiple fronts while the stock drifted 24% below peak.
Full-year revenue hit $10.1 billion, up 21%, and adjusted EPS of $8.93 rose 21.7%, marking the third consecutive year of EPS growth above 20% and beating the $2.26 Q4 consensus estimate by $0.27.
The growth is no longer carried by a single platform: da Vinci 5 (the latest-generation robotic surgery console with Force Feedback instruments that give surgeons tactile sensation) placements more than doubled to 870 systems versus 362 in 2024, Ion (a flexible robotic catheter that threads through airways to biopsy lung tissue) procedures surged 51% to just over 144,000, and Single Port procedures grew 87%, the platform’s highest annual growth since commercial launch.
In January, the FDA cleared the da Vinci 5 system for cardiac procedures, including mitral valve repair and atrial defect repair, opening what CFO Jamie Samath described on the Q4 earnings report as an opportunity of “about 160,000 procedures per year” in the U.S. and Korea alone, with additional geographies pending.
On March 2, Intuitive completed its acquisition of ab medica’s da Vinci and Ion distribution business across Italy, Spain, Portugal, Malta, San Marino and associated territories, adding roughly 250 employees and converting the company’s largest European markets from third-party distribution to direct commercial control.
David Rosa, CEO, stated on the Q4 2025 earnings call that management sees “9 million procedures in direct line of sight” for 2026, up from 7 million in 2024 and 8 million in 2025, driven by stronger clinical validation in benign procedures, new clearances in nipple-sparing mastectomy and cardiac indications, and demographic tailwinds from an aging population.
Intuitive Surgical stock enters 2026 with procedure growth guidance of 13% to 15%, a da Vinci installed base of more than 12,100 systems, free cash flow that more than doubled to $2.5 billion in 2025 from $1.3 billion in 2024, and a cardiac indication that gives the platform access to a surgical category it has never before addressed at scale.
Wall Street’s Take on ISRG Stock
Three platforms accelerating simultaneously is not the story the market is pricing into Intuitive Surgical stock at $458.96 — the stock has been repriced as if the da Vinci 5 ramp introduces margin risk and the 2026 procedure guide of 13% to 15% represents a deceleration, when in fact both are the product of a deliberate, multi-year platform expansion strategy now paying off across three independent growth vectors.
Intuitive Surgical’s normalized EPS reached $8.93 in 2025, up 21.7%, and the Street projects continued compounding to $10.02 in 2026 (up 12.2%) and $11.43 in 2027 (up 14.1%), anchored by the 12,100-system installed base that generates recurring instruments, accessories, and service revenue regardless of new system placement volumes; recurring revenue already represented 81% of Q4 2025 total revenue.
Twenty-four of 35 analysts covering Intuitive Surgical stock rate it a buy or outperform, with a mean price target of $599.24, implying 30.6% upside from the current $458.96 price; consensus is specifically waiting to see whether the da Vinci 5 upgrade cycle drives utilization expansion above the 4% Q4 2025 rate and whether the cardiac rollout converts its 160,000-procedure TAM into measurable revenue contribution in the second half of 2026.
The target spread from $378 to $750 reflects a genuine structural debate: the $378 floor prices in a scenario where tariff headwinds (management guided 1.2% of revenue impact in 2026), slowing Chinese tender wins (competitive intensity with local suppliers intensified in Q4 2025), and ACA subsidy uncertainty clip both procedure growth and margin recovery, while the $750 ceiling assumes cardiac adoption accelerates, ASC expansion begins to compound, and the da Vinci 5 subscription renewal cycle converts to a recurring revenue stream starting Q2 2026.
Priced at roughly 45.8x 2026 consensus EPS of $10.02, Intuitive Surgical stock trades below the 54x forward multiple it commanded in January 2026 and the 58x level from three months prior, despite EPS compounding at 12%-plus annually through 2028 and a newly cleared cardiac TAM with no historical revenue equivalent in the model, leaving Intuitive Surgical stock appearing undervalued against its own recent multiple history and the structural growth the platform expansion implies.
When asked about the line-of-sight procedure count on the Q4 call, IR head Dan Connally confirmed the figure grew from 7 million in 2024 to 9 million in 2026, a 28% expansion in addressable volume in two years, driven by benign procedure validation and new clearances — a reframe that the stock price has not yet absorbed.
On March 18, the FDA flagged a stapler problem linked to four serious injuries and one death involving curved-tip staplers used with the da Vinci system; if the recall widens or generates litigation, it introduces direct reputational and financial risk to the company’s accelerating SP and general surgery procedure growth.
The specific number to watch at Q2 2026 earnings is da Vinci 5 utilization growth relative to the Q4 2025 rate of 4%, paired with any commentary on cardiac early-adopter site results and the MIA+ digital subscription renewal rate, which begins billing in Q2.
Intuitive Surgical Financials
Intuitive Surgical’s revenue grew 20.5% to $10.1 billion in 2025, accelerating from 17.2% growth in 2024, as platform expansion across da Vinci, Ion, and SP combined with 870 da Vinci 5 placements drove broad-based volume gains in both instruments and system revenue.
ISRG stock’s operating income rose 25.4% to $2.95 billion in 2025, outpacing revenue growth for the second consecutive year, expanding operating margins to 29.3% from 28.1% in 2024, as recurring high-margin instruments and accessories revenue (which grew 17% in Q4 alone) increasingly offsets the near-term dilution from da Vinci 5 and Ion manufacturing costs.
The gross margin story is more complex: gross profit grew 17.9% to $6.6 billion, but gross margins compressed to 66.0% in 2025 from 67.5% in 2024, reflecting 95 basis points of tariff impact, higher da Vinci 5 production costs not yet at target, and incremental Ion and service infrastructure spending.
What Does the Valuation Model Say?
The TIKR model prices Intuitive Surgical at a mid-case target of $849.20, implying 85% total return from today’s $458.96 over roughly 4.7 years, built on 12.2% revenue CAGR, 32.9% net income margins, and 12.6% EPS CAGR through 2030 — assumptions that do not yet fully assign value to the cardiac TAM, which contributed zero historical revenue to the model’s base.
ISRG appears undervalued at current levels, trading at 45.8x 2026 EPS against a 12%-plus compounding EPS trajectory, below its own recent multiple range of 54x to 58x, while three simultaneous platform expansions and a new cardiac indication add structural upside the consensus has not yet priced.
The investment hinges on whether Intuitive Surgical’s multi-platform expansion compounds as the 9-million-procedure line-of-sight implies, or whether near-term margin pressure, tariff headwinds, and the stapler recall interrupt the re-rating before the new TAMs deliver revenue.
Low Case ($1,005.05 | 9.4% IRR | 11.0% revenue CAGR | 30.6% net margins)
- Da Vinci 5 upgrade cycle slows as tariff headwinds (guided at 1.2% of 2026 revenue) compress hospital capital budgets, limiting system placements below the 1,721 achieved in 2025 and keeping gross margins at the low end of the 67%-68% 2026 guidance range
- China procedure volume declines as local robotic competitors win a higher share of provincial tenders following the competitive intensity that emerged in Q4 2025, reducing the ~273 remaining quota systems from a revenue contributor to a distraction
- Cardiac rollout proceeds slowly as the planned “measured rollout” with specialized training infrastructure limits adoption to selected U.S. sites through 2026, contributing negligible procedure volume and delaying the 160,000-procedure TAM realization by multiple years
- Revenue compounds at 11.0% annually, net income margins reach 30.6%, and the stock delivers 119.0% total return to 2030 at a 9.4% annualized IRR
Mid Case ($1,338.88 | 13.1% IRR | 12.2% revenue CAGR | 32.9% net margins)
- Da Vinci procedure growth lands in the guided 13% to 15% range for 2026, with ASC expansion beginning to contribute as the XiR refurbished system ecosystem enables higher-volume outpatient centers (roughly 70% of which are already affiliated with existing IDN customers)
- Ion procedures sustain double-digit growth as Intuitive expands ROSE (rapid on-site tissue evaluation) and endobronchial ultrasound integration, building the platform’s standing in the lung cancer detection-to-treatment pathway
- MIA+ digital subscription renewals begin in Q2 2026 at a meaningful rate, converting the deferred revenue from da Vinci 5 launches into a new recurring revenue stream that lifts service revenue per system above the 7% year-over-year Q4 growth rate
- Revenue compounds at 12.2%, net income margins reach 32.9%, and the stock delivers 191.7% total return to 2030 at a 13.1% annualized IRR
High Case ($1,733.02 | 16.5% IRR | 13.5% revenue CAGR | 34.6% net margins)
- Cardiac clearance converts faster than the measured rollout implies as Force Feedback instruments receive regulatory approval, specialized training pathways scale, and surgical society endorsements accelerate adoption across the ~160,000 annual U.S. and Korea procedures in scope
- SP platform procedures sustain 80%-plus growth through 2027 as nipple-sparing mastectomy, broader colorectal clearances, and the full SP stapler launch deepen penetration in thoracic and GYN procedures that were previously laparoscopic-only
- Direct distribution across Italy, Spain, and Portugal (250 employees added March 2) accelerates European procedure volume above the 21% growth rate achieved in 2025, as Intuitive gains direct control over pricing, training, and customer relationships in its three largest OUS distributor markets
- Revenue compounds at 13.5%, net income margins reach 34.6%, and the stock delivers 277.6% total return to 2030 at a 16.5% annualized IRR
Should You Invest in Intuitive Surgical, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ISRG stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Intuitive Surgical, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ISRG stock on TIKR for Free →
